Advertisement

Bronchitis, Bronchiolitis und Lungenemphysem

  • Adrian Gillissen
  • Stefan Zielen
Chapter
  • 114 Downloads

Auszug

Die Bronchitis wird in die akute und die chronische Erkrankungsform eingeteilt. Bei der chronischen Form müssen zusätzlich das Vorhandensein einer zusätzlichen Atemwegsobstruktion und Sekundärveränderungen, insbesondere das Lungenemphysem, berücksichtigt werden.

Literatur

  1. Ball P, Harris M, Lowson D, Tillotson G, Wilson R. Acute infective exacerbtions of chronic bronchitis. QJ Med 1995; 88: 61–68Google Scholar
  2. Barnes P J. Inhaled Corticosteroids are not beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 342–344PubMedGoogle Scholar
  3. Bolser D C. Cough suppressant and pharmacologic protussive therapy: ACCP evidence-based clinical practice guidelines. Chest 2006; 129: 238–249CrossRefGoogle Scholar
  4. Braman S S. Chronic dough due to acute bronchitis: ACCP evidence-baed clinical practice guidelines. Chest 2006; 129: 95–103CrossRefGoogle Scholar
  5. Burge P S, Calverley P M A, Jones P W, Spencer S, Anderson J. Randomised, placebo-controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease; the ISOLDE trial. Br Med J 2000; 320: 1297–1303CrossRefGoogle Scholar
  6. Calverley P M A, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and for-moterol in chronic obstructive pulmonary disease. Eur RespirJ 2003; 22: 912–919CrossRefGoogle Scholar
  7. Decramer M, Rutten-von-Molken M P M H, Dekhuijzen P N P, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCHUS): a randomised placebo-controlled trial. Lancet 2005; 365: 1552–1560PubMedCrossRefGoogle Scholar
  8. Eller J, Ede A, Schaberg T, Niederman M S, Mauch H, Lode H. Infective exazerbations of chronic obstructive pulmonary disease. Relation between bacteriologic etiology and lung function. Chest 1998; 113: 1542–548PubMedGoogle Scholar
  9. Fujimoto T, Teschler H, Hillejan L, Zaboura G, Stamatis G. Long-term results of lung volume reduction surgery. Eur J Cardiothorac Surg 2003; 21: 483–488CrossRefGoogle Scholar
  10. Gillissen A, Buhl R, Kardos P, et al. Management der akuten Exaz-erbation der chronisch-obstruktiven Lungenerkrankung (COPD). Dtsch Med Wschr 2003; 128: 1721–1727PubMedCrossRefGoogle Scholar
  11. Gillissen A, Tasci S, Ewig S, Schäfer H, Zielen S. Sinn und Unsinn von Antitussiva. Internist 2001; 42: 134–142PubMedCrossRefGoogle Scholar
  12. GOLD Executive Committee. Global initiative for chronic obstructive lung disease. www goldcopd com 2006Google Scholar
  13. Gompertz S, O’Brien C, Bayley D L, Hill S L, Stockley R A. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J 2001; 17: 1112–1119PubMedCrossRefGoogle Scholar
  14. Grunsven van PM, Schayckvan C P, Derenne J P, et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax 1999; 54: 7–14PubMedCrossRefGoogle Scholar
  15. Höffken G, Lorenz J, Kern W, et al. S3-Leitlinie zu Epidemiologie, Diagnostik, antimikrobieller Therapie und Management von erwachsenen Patienten mit ambulant erworbenen tiefen Atemwegsinfektion. Pneumologie 2005; 59: 612–664PubMedCrossRefGoogle Scholar
  16. Hurt R D, Sachs D P, Glover E D, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337: 1195–1202PubMedCrossRefGoogle Scholar
  17. Irwing R S, Boulet L-P, Cloutier M M, et al. Managing cough as a defense mechanism and as a symptom. A consensus panel report of the Amercian Chest Physicians. Chest 1998; 114: 133–181Google Scholar
  18. Jorenby D E, Leischow S J, Niedes M A, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340:685–691PubMedCrossRefGoogle Scholar
  19. Juergens U R, Dethlefsen U, Steinkamp G, Gillissen A, Repges R, Vetter H. Anti-inflammatory activity of 1.8-Cineol (eucalyptol) in bronchial asthma: a double-blind placebo-controlled trial. Resp Med 2003; 97:250–256CrossRefGoogle Scholar
  20. Kardos P, Gebhardt T, Decot E. Chronisch persistierender Husten (CPH): Therapie. Pneumologie 1995; 49:47–54PubMedGoogle Scholar
  21. Köhnlein T, Welte T (Hrsg). AIpha-1 Antitrypsin-Mangel. Bremen-London-Boston: Uni-Med Verlag AG; 2003; 1–111Google Scholar

Reference ID

  1. Magnussen H, Goeckenjan G, Köhler D, et al. Leitlinien zur Langzeit-Sauerstofftherapie. Pneumologie 2001; 55:454–464PubMedCrossRefGoogle Scholar
  2. Nannini L, Lasserson T J, Poole P. Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2003; 4:CD003794PubMedGoogle Scholar
  3. National Emphysema Treatment Research Group, National. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348:2059–2073CrossRefGoogle Scholar
  4. National Institute for Clinical Excellence. Chronic obstructive pulmonary disease: Management of adults with chronic obstructive pulmonary disease in primary and secondary care. www nice org uk/ 2004Google Scholar
  5. Niewoehner D E, Collins D, Erbland M L. Relation of FEV, to clinical outcomes during exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161:1201–1205PubMedGoogle Scholar
  6. Niewoehner D E, Erbland M L, Deupree R H, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999; 340:1941–1947PubMedCrossRefGoogle Scholar
  7. Noord van J A, Aumann J, Janssens E, et al. Comparison of tiotro-pium once daily, formoterol twice daily and combinded once daily in patients with COPD. Eur Respir J 2005; 26:214–222PubMedCrossRefGoogle Scholar
  8. Paggiaro P L, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998; 351:773–780PubMedCrossRefGoogle Scholar
  9. Scanlon PD, Connett JE, Waller L A, Altose MD, Bailey WC, Buist A S. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000; 161:381–390PubMedGoogle Scholar
  10. Schäfer H, Ewig S, Gillissen A. Therapie der schweren Exazerba-tion bei chronisch obstruktiver Lungenerkrankung (COPD). Intensivmed 2000; 37:176–186CrossRefGoogle Scholar
  11. Soler N, Torres A, Ewig S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998; 157:1498–1505PubMedGoogle Scholar
  12. Szafranski W, Ramirez A, Menga G, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21:74–81PubMedCrossRefGoogle Scholar
  13. Valk van der P, Monninkhoff E, Palen van der J, Zielhuis G, Heerwaarden van C. Effect of discontinuation of inhalaed corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med 2002; 166:1358–1363PubMedCrossRefGoogle Scholar
  14. Vestbo J, Pauwels R A, Anderson J A, Jones P W, Calverley P M A. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary diasease. Thorax 2005; 60:301–304PubMedCrossRefGoogle Scholar
  15. Vestbo J, Sørensen T, Langer P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 355:1819–1823CrossRefGoogle Scholar
  16. Vogel F, Worth H, Adam D, et al. Rationale Therapie bakterieller Atemwegsinfektionen. Empfehlung der Paul-Ehrlich-Gesellschaft für Chemotherapie und der Deutschen Atemwegsliga. Chemotherapie J 2000; 9:3–23Google Scholar
  17. Worth H, Buhl R, Cegla U et al. Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem(COPD). Pneumologie 2002, 56: 704–738PubMedCrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag Heidelberg 2007

Authors and Affiliations

  • Adrian Gillissen
    • 1
  • Stefan Zielen
    • 2
  1. 1.Robert-Koch-KlinikStädtisches Klinikum St. Georg LeipzigLeipzig
  2. 2.Zentrum für Kinderheilkunde und Jugendmedizin Bereich Allergologie und PneumologieKlinikum der Johann Wolfgang Goethe-UniversitätFrankfurt am Main

Personalised recommendations